Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7P3V

B-Raf V600E structure bound to a new inhibitor

Summary for 7P3V
Entry DOI10.2210/pdb7p3v/pdb
DescriptorSerine/threonine-protein kinase B-raf, ~{N}-[3-[5-(2-azanylpyrimidin-4-yl)-2-[(3~{S})-morpholin-3-yl]-1,3-thiazol-4-yl]-2-fluoranyl-phenyl]-2,5-bis(fluoranyl)benzenesulfonamide (3 entities in total)
Functional Keywordsinhibitor complex, drug design, domain swapping, oncoprotein
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight63937.20
Authors
Schneider, M.,Gelin, M.,Cohen-Gonsaud, M.,Labesse, G. (deposition date: 2021-07-08, release date: 2021-11-03, Last modification date: 2024-01-31)
Primary citationSchneider, M.,Delfosse, V.,Gelin, M.,Grimaldi, M.,Granell, M.,Heriaud, L.,Pons, J.L.,Cohen Gonsaud, M.,Balaguer, P.,Bourguet, W.,Labesse, G.
Structure-Based and Knowledge-Informed Design of B-Raf Inhibitors Devoid of Deleterious PXR Binding.
J.Med.Chem., 65:1552-1566, 2022
Cited by
PubMed Abstract: Dabrafenib is an anticancer drug currently used in the clinics, alone or in combination. However, dabrafenib was recently shown to potently activate the human nuclear receptor pregnane X receptor (PXR). PXR activation increases the clearance of various chemicals and drugs, including dabrafenib itself. It may also enhance cell proliferation and tumor aggressiveness. Therefore, there is a need for rational design of a potent protein kinase B-Raf inhibitor devoid of binding to the secondary target PXR and resisting rapid metabolism. By determining the crystal structure of dabrafenib bound to PXR and analyzing its mode of binding to both PXR and its primary target, B-Raf-V600E, we were able to derive new compounds with nanomolar activity against B-Raf and no detectable affinity for PXR. The crystal structure of B-Raf in complex with our lead compound revealed a subdomain swapping of the activation loop with potentially important functional implications for a prolonged inhibition of B-Raf-V600E.
PubMed: 34958586
DOI: 10.1021/acs.jmedchem.1c01354
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.37 Å)
Structure validation

239149

数据于2025-07-23公开中

PDB statisticsPDBj update infoContact PDBjnumon